Drug Trial Radar · NCT04627428
Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
18
Actual
Start
Apr 5, 2022
Primary completion
Aug 5, 2028
Study completion Aug 5, 2028
Sponsor
- Lead sponsor
- Luxa Biotechnology, LLCIndustry
- Sponsor type
- Industry
- Collaborators
- National Institutes of Health (NIH); National Eye Institute (NEI); Regenerative Research Foundation; California Institute for Regenerative Medicine (CIRM)
- First posted
- Nov 13, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of the study is evaluation of the safety and tolerability of RPESC-RPE-4W as therapy for dry AMD.
Conditions
- Dry Age-related Macular Degeneration
Interventions
RPESC-RPE-4WBiological
RPESC-RPE-4W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of RPESC-RPE-4W transplantationTime frame: 24 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Retina Vitreous Associates Medical Group
Beverly Hills, California
Spencer Center for Vision Research
Palo Alto, California
University of Michigan Kellogg Eye Center
Ann Arbor, Michigan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.